Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: the THETIS study
ISBT Education. Lai Y. Nov 27, 2017; 203507
Topic: Clinical trials
Yong Rong Lai
Yong Rong Lai
This content is exclusively available for members.

You may become an ISBT member here.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation the participant will be able to:

- Review incidence of thalassemia carriers in China and worldwide
- Relate studies and trials evaluating iron overload and chelation in Chinese thalassemia major and Non Transfusion Dependent Thalassemia (NTDT) patients
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings